Mostrar el registro sencillo del ítem

Real-life use of temocillin in the treatment of bone and joint infections due to extended spectrum β-lactamase-producing Enterobacterales.

dc.rights.licenseopenen_US
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorLAHOUATI, Marin
dc.contributor.authorBROUSSE, Xavier
dc.contributor.authorDIAS MEIRELES, Vasco
dc.contributor.authorRIGNOL, Laurine
dc.contributor.authorBIENTZ, Léa
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorXUEREB, Fabien
dc.contributor.authorDAUCHY, Frédéric-Antoine
dc.date.accessioned2024-12-09T11:05:42Z
dc.date.available2024-12-09T11:05:42Z
dc.date.issued2024-12-01
dc.identifier.issn2632-1823en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/203796
dc.description.abstractEnThe aim of this study is to describe the real-life use of temocillin in bone and joint infections (BJI). We performed a monocentric retrospective study, including all patients treated by temocillin for a BJI due to extended spectrum β-lactamase-producing Enterobacterales (ESBL-E) between 1 January 2015 and 31 December 2022. Outcomes were evaluated at least 3 months after the end of antimicrobial treatment. Clinical cure was defined as the absence of recurrence of BJI during follow-up among patients who completed at least 7 days of temocillin. If the patient discontinued temocillin due to ineffectiveness, the outcome was considered to be unfavourable. Seventeen patients were treated with temocillin for ESBL-E associated BJI during the study period. Infections included osteomyelitis of the foot (7/17; 41.2%), femoral osteomyelitis (4/17; 23.5%), disco-vertebral infections (2/17; 11.8%), total knee prosthesis infections (2/17; 11.8%) and total hip prosthesis infections (2/17; 11.8%). All patients except one ( = 16) had surgical management of the infection. The main bacteria identified were the complex ( = 9) and ( = 5). The median daily dose was 6 g for a median duration of 42 days (IQR 14-42 days). The median duration of follow-up was 12 months (IQR 5.25-14.5). Overall, 12 patients completed at least 3 months of follow-up, and clinical cure was observed in eight of them (8/12; 66.7%). So far, this is the first report of BJI successfully treated with temocillin. This suggests that temocillin may be an alternative to treat BJI involving difficult-to-treat Enterobacterales when oral therapy is not available.
dc.language.isoENen_US
dc.title.enReal-life use of temocillin in the treatment of bone and joint infections due to extended spectrum β-lactamase-producing Enterobacterales.
dc.title.alternativeJAC Antimicrob Resisten_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1093/jacamr/dlae171en_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologieen_US
dc.identifier.pubmed39512359en_US
bordeaux.journalJAC-Antimicrobial Resistanceen_US
bordeaux.pagedlae171en_US
bordeaux.volume6en_US
bordeaux.hal.laboratoriesBiologie des maladies cardiovasculaires (BMC) - UMR 1034en_US
bordeaux.issue6en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.identifierhal-04826727
hal.version1
hal.date.transferred2024-12-09T11:05:44Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=JAC-Antimicrobial%20Resistance&rft.date=2024-12-01&rft.volume=6&rft.issue=6&rft.spage=dlae171&rft.epage=dlae171&rft.eissn=2632-1823&rft.issn=2632-1823&rft.au=LAHOUATI,%20Marin&BROUSSE,%20Xavier&DIAS%20MEIRELES,%20Vasco&RIGNOL,%20Laurine&BIENTZ,%20L%C3%A9a&rft.genre=article


Archivos en el ítem

ArchivosTamañoFormatoVer

No hay archivos asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem